|
US5166315A
(en)
|
1989-12-20 |
1992-11-24 |
Anti-Gene Development Group |
Sequence-specific binding polymers for duplex nucleic acids
|
|
US5217866A
(en)
|
1985-03-15 |
1993-06-08 |
Anti-Gene Development Group |
Polynucleotide assay reagent and method
|
|
US5521063A
(en)
|
1985-03-15 |
1996-05-28 |
Antivirals Inc. |
Polynucleotide reagent containing chiral subunits and methods of use
|
|
US5235033A
(en)
|
1985-03-15 |
1993-08-10 |
Anti-Gene Development Group |
Alpha-morpholino ribonucleoside derivatives and polymers thereof
|
|
US5185444A
(en)
|
1985-03-15 |
1993-02-09 |
Anti-Gene Deveopment Group |
Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
|
|
US5506337A
(en)
|
1985-03-15 |
1996-04-09 |
Antivirals Inc. |
Morpholino-subunit combinatorial library and method
|
|
US20030087861A1
(en)
|
2001-05-17 |
2003-05-08 |
Iversen Patrick L |
Combined approach to treatment of cancer using a c-myc antisense oligomer
|
|
US6828105B2
(en)
|
2001-10-16 |
2004-12-07 |
Avi Biopharma, Inc. |
Antisense antiviral agent and method for treating ssRNA viral infection
|
|
WO2005072527A2
(en)
|
2004-01-23 |
2005-08-11 |
Avi Biopharma, Inc. |
Antisense oligomers and methods for inducing immune tolerance and immunosuppression
|
|
US7402574B2
(en)
|
2004-03-12 |
2008-07-22 |
Avi Biopharma, Inc. |
Antisense composition and method for treating cancer
|
|
US8357664B2
(en)
|
2004-10-26 |
2013-01-22 |
Avi Biopharma, Inc. |
Antisense antiviral compound and method for treating influenza viral infection
|
|
US8067571B2
(en)
|
2005-07-13 |
2011-11-29 |
Avi Biopharma, Inc. |
Antibacterial antisense oligonucleotide and method
|
|
AU2006287530A1
(en)
|
2005-09-08 |
2007-03-15 |
Sarepta Therapeutics, Inc. |
Antisense antiviral compound and method for treating picornavirus infection
|
|
LT2735568T
(lt)
|
2006-05-10 |
2017-11-27 |
Sarepta Therapeutics, Inc. |
Oligonukleotido analogai, turintys katijonines jungtis tarp subvienetų
|
|
CA2691673A1
(en)
|
2007-06-29 |
2009-01-08 |
Avi Biopharma, Inc. |
Tissue specific peptide conjugates and methods
|
|
US20100016215A1
(en)
|
2007-06-29 |
2010-01-21 |
Avi Biopharma, Inc. |
Compound and method for treating myotonic dystrophy
|
|
US8299206B2
(en)
|
2007-11-15 |
2012-10-30 |
Avi Biopharma, Inc. |
Method of synthesis of morpholino oligomers
|
|
US8076476B2
(en)
|
2007-11-15 |
2011-12-13 |
Avi Biopharma, Inc. |
Synthesis of morpholino oligomers using doubly protected guanine morpholino subunits
|
|
EP3133160B1
(en)
|
2008-10-24 |
2018-12-12 |
Sarepta Therapeutics, Inc. |
Exon skipping compositions for dmd
|
|
US20100210989A1
(en)
|
2008-12-23 |
2010-08-19 |
Janet Lesley Macpherson |
Processing blood
|
|
CN103154009B
(zh)
|
2010-09-30 |
2015-06-10 |
日本新药株式会社 |
吗啉基核酸衍生物
|
|
US9161948B2
(en)
|
2011-05-05 |
2015-10-20 |
Sarepta Therapeutics, Inc. |
Peptide oligonucleotide conjugates
|
|
ES2727481T3
(es)
|
2011-11-30 |
2019-10-16 |
Sarepta Therapeutics Inc |
Inclusión inducida de exón en atrofia muscular espinal
|
|
JP6477464B2
(ja)
|
2013-05-24 |
2019-03-06 |
味の素株式会社 |
モルフォリノオリゴヌクレオチドの製造方法
|
|
PT3149025T
(pt)
*
|
2014-05-21 |
2019-08-01 |
Entrada Therapeutics Inc |
Peptídeos penetrantes de células e métodos de fabrico e utilização dos mesmos
|
|
US11472824B2
(en)
|
2016-05-24 |
2022-10-18 |
Sarepta Therapeutics, Inc. |
Processes for preparing phosphorodiamidate morpholino oligomers
|
|
TW202500573A
(zh)
*
|
2016-11-22 |
2025-01-01 |
俄亥俄州立創新基金會 |
細胞穿透肽序列
|
|
EA201991450A1
(ru)
|
2017-09-22 |
2019-12-30 |
Сарепта Терапьютикс, Инк. |
Конъюгаты олигомеров для пропуска экзона при мышечной дистрофии
|
|
TWI812647B
(zh)
|
2017-09-25 |
2023-08-21 |
美商薩羅塔治療公司 |
經由速流合成以製備磷醯二胺嗎啉代寡聚物之製程
|
|
WO2019165183A1
(en)
*
|
2018-02-22 |
2019-08-29 |
Entrada Therapeutics, Inc. |
Compositions and methods for treating mitochondrial neurogastrointestinal encephalopathy
|
|
US10765760B2
(en)
|
2018-05-29 |
2020-09-08 |
Sarepta Therapeutics, Inc. |
Exon skipping oligomer conjugates for muscular dystrophy
|
|
US12012427B2
(en)
|
2019-10-31 |
2024-06-18 |
Indian Association For The Cultivation Of Science |
Synthesis of Fmoc-protected morpholino monomers and their use in the synthesis of morpholino oligomer
|
|
JP2023553360A
(ja)
|
2020-12-11 |
2023-12-21 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
ポリ-モルホリノオリゴヌクレオチドギャップマー
|
|
IL308353A
(en)
*
|
2021-05-10 |
2024-01-01 |
Entrada Therapeutics Inc |
Compositions and methods for modulating tissue distribution of intracellular therapies
|
|
US20250228953A1
(en)
*
|
2021-11-08 |
2025-07-17 |
Entrada Therapeutics, Inc. |
Intracellular targeting of oligonucleotides
|